DcR3 expression was also significantly higher in SCLC cancer tissues compared to normal lung tissue,17 thus inhibition of DcR3 expression by interfering with upstream Sp1 pathway may provide a novel immunotherapeutic target to restore antitumor immune response in low‐risk group SCLC patients. This evidence concerns the gene TNFRSF6B and cancer.